Literature DB >> 3031291

Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives.

W S Marshall, T Goodson, G J Cullinan, D Swanson-Bean, K D Haisch, L E Rinkema, J H Fleisch.   

Abstract

A series of derivatives of 2,4-dihydroxy-3-propylacetophenone(1) were prepared and examined for their ability to block leukotriene D4 (LTD4) induced contraction of guinea pig ileum. Straight-chain carboxylic acids where the carboxyl group was separated from the acetophenone moiety by varying numbers of methylenes were evaluated, and maximum activity was obtained with the pentamethylene acid (6). Examination of ring substitution showed that the 2-propyl-3-hydroxy-4-acetyl substitution pattern was required for maximum LTD4 antagonist activity. Additional chain terminal groups were examined, and the acidic 5-tetrazolyl group separated from the acetophenone moiety by four to seven methylenes (26, 23, 27, 28) gave excellent in vitro and in vivo activities. Compound 26 (LY171883) had the best balance of in vitro and in vivo activity. It lacked bronchospastic activity at the doses administered and has been chosen for clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3031291     DOI: 10.1021/jm00387a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Leukotriene (LT) receptor antagonists. Heterocycle-linked tetrazoles and carboxylic acids. LY203647.

Authors:  W S Marshall; S K Sigmund; C A Whitesitt; S L Lifer; C R Roman; L E Rinkema; R A Hahn; J H Fleisch
Journal:  Agents Actions       Date:  1989-06

2.  Tetrazole synthesis via the palladium-catalyzed three component coupling reaction.

Authors:  Shin Kamijo; Tienan Jin; Zhibao Huo; Young Soo Gyoung; Jae-Goo Shim; Yoshinori Yamamoto
Journal:  Mol Divers       Date:  2003       Impact factor: 2.943

3.  Species specificity in the blood cholesterol-lowering effect of YM-16638.

Authors:  S Goto; T Shimokawa; T Ugawa; N Hisamichi; Y Masuyama; Y Iizumi; N Sato; T Takenaka; T Kodama
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.